SOLUTIONS DEVELOPS GRAPHENE-BASED INK WITH 99% VIRUCIDAL ACTIVITY AGAINST COVID-19
After five months of optimization, Zen Graphene Solutions Ltd. (ZEN.V) has developed a novel graphene-based virucidal ink with 99-per-cent effectiveness against COVID-19.
- Zen's virucidal ink is 99 per cent effective against the COVID-19 virus;
- Zen's virucidal ink was still 99 per cent effective a minimum of 35 days after application to N95 mask material;
- Zen is now developing plans to expedite commercialization of this product, pending regulatory approval;
- Zen has filed a provisional patent for this graphene-based virucidal product;
- Zen is beginning anti-bacterial and anti-fungal tests utilizing its proprietary ink formulation.
The company has received results from the latest round of testing of its proprietary graphene-based virucidal ink formulation at Western University's ImPaKT facility, a biosafety level 3 laboratory. Two graphene-based ink samples at different concentrations were applied to N95 mask filtration media and then exposed to the SARS-CoV-2 virus that causes COVID-19 and tested for anti-viral properties in accordance with ISO 18184:2019. Very significant virucidal activity was recorded and reported, achieving 99-per-cent inactivation of the virus for both samples in three separate tests each and verified through a second round of testing. Of significance, the anti-viral effect of the second round of testing was on material that was prepared 35 days earlier demonstrating the continuing virucidal activity of Zen's proprietary ink. For those interested in seeing the report, please contact the company directly.
The research and development of this anti-viral ink formulation was conducted entirely by Zen's research team at its facility in Guelph, Ont., using a graphene product that was produced from its Albany Pure graphite.
Zen is now developing plans to bring this novel virucidal ink to commercial production, including working with regulatory authorities and government agencies to fast-track this product to Canadian and global markets to help the fight against the coronavirus pandemic. Zen is expanding the testing of this graphene-based ink formulation to include pathogenic bacteria and fungi and will report on these tests as soon as the results are available.
Chief executive officer Dr. Francis Dube commented: "These recent results have dramatically exceeded our expectations with our ink achieving 99-per-cent virucidal activity against the SARS-CoV-2 virus 35 days after production of the samples. I am very proud of our research and development team for their exceptional work in developing this novel formulation. We are excited about the role our ink can play in the fight against this global pandemic and are moving quickly to mobilize our resources to bring this product to market."
The company is not making any express or implied claims that its products have the ability to cure or contain the COVID-19 virus at this time.
About Zen Graphene Solutions Ltd.
Zen is an emerging graphene technology solutions company with a focus on the development of graphene-based nanomaterial products and applications. The unique Albany Graphite project provides the company with a potential competitive advantage in the graphene market as independent labs in Japan, the United Kingdom, Israel, the United States and Canada have independently demonstrated that Zen's Albany Pure graphite is an ideal precursor material that easily converts (exfoliates) to graphene using a variety of mechanical, chemical and electrochemical methods.